BioPharm International Editors

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

European scientists have discovered a method to improve the efficiency of the pharmaceutical production through plant biotechnology.

New research finds that recurrent head and neck tumors have gene mutations that could be vulnerable to the cancer drug dasatinib.

Immunovaccine reports enhanced cancer vaccine combination therapies at 2014 AACR Annual Meeting.

Sanofi and Genzyme to resubmit FDA application for approval of Lemtrada, for the treatment of relapsing forms of multiple sclerosis.

Novartis delivers 2 million treatments of its pediatric antimalarial to Zambia in collaboration with Malaria No More's Power of One campaign.

Vetter launches new serialization process to support track-and-trace efforts.

RCA opens a new office in Warsaw, Poland.

Baxter announces plans to split into two independent companies by mid-2015.

Pfizer intends to submit a biologics license application for its investigational Meningococcal B vaccine candidate, Bivalent rlp2086, to FDA by mid-2014.

XstalBio Analytics' approach to vaccine analysis and formulation is aimed at understanding the antigen– adjuvant interaction.

FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.

Novartis has launched the prefilled syringe formulation of Lucentis (ranibizumab) in Germany, with other markets to follow throughout 2014. The prefilled syringe formulation has been specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.

Looking to improve patient access to new medicines, EMA creates a pilot project to explore an adaptive licensing approach with real medicines in development.

FDA clarifies recommendations for injectable drug products packaged in vials and ampules.

Walker Barrier Systems builds eight mobile clean rooms for the Texas A&M Center for Innovation in Advanced Development and Manufacturing.

$2.6 billion transaction combines Patheon and DSM Pharmaceutical to create CDMO, DPx.

Almac expands technical, project, and operational resources in Asia.

HHS plan makes progress in ensuring availability of safe vaccines.

Johnson Controls launches Integrated Laboratory Services for R&D facility operations and scientific productivity.

CPhI report shows R&D market diversifying with increased partnerships, mergers, and revenue sharing models.

Cobra Biologics and BioCancell announce an agreement to manufacture BioCancell's BC-821 cancer drug.

Agencies extend successful pilot program to further harmonization of QbD topics.

Novartis calls for more research to understand and find treatments for rare disease.

New guidance from FDA asks for documentation of CMC postapproval manufacturing changes.

Waters celebrates ten&$45;year anniversary of the ACQUITY UPLC System.

Moody's Investor Service reports AbbVie, Amgen, and Roche are the most exposed to biosimilar competition.

FDA approves the orphan drug Myalept for the treatment of leptin deficiency.

Novartis provides its second US university with Bexsero for the treatment of meningitis B.